

TorreyPines Therapeutics, Inc.  
Form 8-K  
October 22, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 22, 2007**

**TORREYPINES THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other  
Jurisdiction  
of Incorporation)

**000-25571**  
(Commission  
File Number)

**86-0883978**  
(IRS Employer  
Identification No.)

**11085 North Torrey Pines Road, Suite 300, La Jolla, CA**  
(Address of Principal Executive Offices)

**92037**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 623-5665**

(Former Name or Former Address, if Changed Since Last Report.)

## Edgar Filing: TorreyPines Therapeutics, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On October 22, 2007, TorreyPines Therapeutics, Inc. issued a press release announcing the results of its Phase II clinical trial evaluating tezampanel as a treatment for acute migraine. A copy of the press release is attached as Exhibit 99.1

The press release announced that TorreyPines will hold a conference call and webcast today at 9:00 a.m. Eastern time to discuss the trial. A copy of the slides that will be presented on the webcast is attached hereto as Exhibit 99.2.

**Item 9.01. Financial Statements and Exhibits**

(d) The following exhibit is furnished herewith:

99.1 Press release dated October 22, 2007

99.2 Slides to be presented on webcast on October 22, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TORREYPINES THERAPEUTICS, INC.

Date: October 22, 2007

By: /s/ Craig Johnson  
Name: Craig Johnson  
Title: Vice President, Finance and  
Chief Financial Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated October 22, 2007
99.2	Slides to be presented on webcast on October 22, 2007